Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation

BACKGROUND: Phase III trials evaluating the efficacy of gefitinib (IRESSA) in non-small cell lung cancer (NSCLC) lend support to the need for improved patient selection in terms of gefitinib use. Mutation of the epidermal growth factor receptor (EGFR) gene is reported to be associated with clinical...

Full description

Saved in:
Bibliographic Details
Main Authors: Noro, Rintaro, Gemma, Akihiko, Kosaihira, Seiji, Kokubo, Yutaka, Chen, Mingwei, Seike, Masahiro, Kataoka, Kiyoko, Matsuda, Kuniko, Okano, Tetsuya, Minegishi, Yuji, Yoshimura, Akinobu, Kudoh, Shoji
Format: Artigo
Language:Inglês
Published: BioMed Central 2006
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC1698934/
https://ncbi.nlm.nih.gov/pubmed/17150102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-6-277
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items